Tissue microarray analysis of FAS, Bcl-2, Bcl-x, ER, PgR, Hsp60, p53 and Her2-neu in breast carcinoma

Anticancer Research

Volumn 26, Issue 4 B, 2006, Pages 2983-2987

  Sebastiani, Valeria ^a   Botti, Claudio ^b   Di Tondo, Ugo ^a   Visca, Paolo ^b   Pizzuti, Laura ^a   Santeusanio, Giuseppe ^c   Alo, Piero Luigi ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c S EUGENIO HOSPITAL   (Italy)

Author keywords

bcl 2; bcl x; Breast carcinoma; FAS; Her2 neu; Hsp60; p53; Prognosis; TMA

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FAS ANTIGEN; FATTY ACID SYNTHASE; HEAT SHOCK PROTEIN 60; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P53;

ARTICLE; BREAST CARCINOMA; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY;

BCL-X PROTEIN; BREAST NEOPLASMS; CHAPERONIN 60; FATTY ACID SYNTHETASE COMPLEX; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; PROTEIN ARRAY ANALYSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33746710376     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Richie RC and Swanson JO: Breast cancer: a review of the literature. J Insur Med 35(2): 85-101, 2003.
2. Hutter RV: The influence of pathologic factors on breast cancer management. Cancer 46: 961-976, 1980.
3. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhrost J, Mihatsch MJ, Sauter G and Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7): 844-847, 1998.
4. Page DL and Anderson TS: Diagnostic Histopathology of the Breast (First edition). Churchill-Livingstone, pp. 193-268, 1992.
5. Bloom HJ and Richardson WW: Histological grading and prognosis in breast cancer. A study of 1049 cases of which 359 have been followed for fifteen years. Br J Cancer 11: 359-377, 1957.
6. Spiessl B (ed.): International Union Against Cancer. TNM-atlas: Illustrated Guide to TNM/pTNM-classification of Malignant Tumors (Third edition). Berlin: Springer-Verlag, pp. 174-183, 1989.
7. Berman JJ, Edgerton ME and Friedman BA: The tissue microarray data exchange specification: a community based, open source tool for sharing tissue microarray data. BMC Med Inform Decis Mak 3(1): 5, 2003.
8. Wakil SJ: Fatty acid synthase: a proficient multifunctional enzyme. Biochemistry 28: 4523-4530, 1989.
9. Kuhajda FP, Piantadosi S and Pasternack GR: Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of disease. N Engl J Med 321(10): 636-641, 1989.
10. Kuhajda FP and Eggleston JC: Pregnancy-associated plasma protein A and extensive necrosis: clinically significant predictors of early recurrence in stage I estrogen receptor-negative breast carcinoma. Lab Invest 53(1): 101-107, 1985.
11. Wang Y, Kuhajda FP, Li JN, Pizer ES, Han WF, Sokoll LJ and Chan DW: Fatty acid synthase expression in human breast cancer cell culture supernatants and in breast cancer patients. Canc Lett 167(1): 99-104, 2001.
12. Alo P, Visca P, Framarino ML, Botti C, Monaco S, Sebastiani V, Serpieri DE and Di Tondo U: Immunohistochemical study of fatty acid synthase in ovarian neoplasms. Oncol Rep 7(6): 1383-1388, 2000.
13. Epstein JI, Carmichael M and Partin AW: OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology 45: 81-86, 1995.
14. Alo PL, Galati GM, Sebastiani V, Ricci F, Visca P, Mariani L, Romagnoli F, Lombardi G and Di Tondo U: Fatty acid synthase expression in Paget's disease of the vulva. Int J Gynaecol Pathol 24(4): 404-408, 2005.
15. Rashid A, Pizer ES, Moga M, Milgraum LZ, Zahurak M, Pasternack GR, Kuhajda FP and Hamilton SR: Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol 150(1): 201-208, 1997.
16. Visca P, Sebastiani V, Pizer ES, Botti C, De Carli P, Filippi S, Monaco S and Alo PL: Immunohistochemical expression and prognostic significance of fatty acid synthase and GLUT1 in bladder carcinoma. Anticancer Res 23(1A): 335-339, 2003.
17. Nemoto T, Terashima S, Kogure M, Hoshino Y, Kusakabe T, Suzuki T and Gotoh M: Overexpression of fatty acid synthase in oesophageal squamous cell dysplasia and carcinoma. Pathobiology 69: 297-303, 2001.
18. Sebastiani V, Visca P, Botti C, Santeusanio G, Galati GM, Piccini V, Capezzone De Joannon B, Di Tondo U and Alo PL: Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma. Gynaecol Oncol 92(1): 101-105, 2004.
19. Camassei FD, Cozza R, Acquaviva A, Jenkner A, Rava L, Gareri R, Donfrancesco A, Bosman C, Vadaca P, Hadjistilianou T and Boldrini R: Expression of the lipogenic enzyme fatty acid synthase in retinoblastoma and its correlation with tumor aggressiveness. Invest Opthalmol Vis Sci 44(6): 2399-2403, 2003.
20. Gabrielson EW, Pinn ML, Testa JR and Kuhajda FP: Increased fatty acid synthase is a therapeutic target in mesothelioma. Clin Cancer Res 7(1): 153-157, 2001.
21. Innocenzi D, Alo PL, Balzani A, Sebastiani V, Silipo V, La Torre G, Ricciardi G, Bosman C and Calvieri S: Fatty acid synthase expression in melanoma. J Cutan Pathol 30(1): 23-28, 2003.
22. Takahiro T, Shinichi K and Toshimitsu S: Expression of fatty acid synthase as a prognostic indicator in soft tissue sarcomas. Clin Cancer Res 9(6): 2204-2212, 2003.
23. Alo PL, Visca P, Marci A, Botti C, Mangoni A and Di Tondo U: Expression of fatty acid synthase as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77(3): 474-482, 1996.
24. Pinto AE, Andre S, Laranjeira C and Suares J: Correlation of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB2 with biological markers of proliferation and overall survival in breast cancer. Pathology 37(1): 45-50, 2005.
25. Schiller AB, Clark WS, Cotsonis G, Lawson D, DeRose PB and Cohen C: Image cytometric bcl-2:bax and bcl-2:bcl-x ratios in invasive breast carcinoma: correlation with prognosis. Cytometry 50(4): 203-209, 2002.
26. MacCarthy-Morrogh L, Wood L, Brimmell M, Johnson WMP and Packham G: Identification of a novel human Bcl-x promoter and exon. Oncogene 19(48): 5534-5538, 2000.
27. Kondo T, Matsuda T, Tashima M, Umehara H, Domae N, Yokoyama K, Uchiyama T and Okazaki T: Suppression of heat shock protein-70 by ceramide in heat shock-induced HL-60 cell apoptosis. J Biol Chem 275(12): 8872-8879, 2000.
28. Coronato S, Di Girolamo W, Salas M, Spinelli O and Laguens G: Biologia de las proteinas del shock termico. Medicina (B. Aires) 59(5 Pt 1): 477-486, 1999.
29. Gupta S and Knowlton AA: Cytosolic heat shock protein 60, hypoxia, and apoptosis. Circulation 106(21): 2727-2733, 2002.
30. Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Bachleitner T, Roka S, Fitzal F, Kandioler D, Sporn E, Friedl J, Mittlbock M and Jakesz R: Do we need HER2-neu testing for all patients with primary breast carcinoma? Cancer 98(12): 2547-2553, 2003.